Why Gilead Sciences (GILD) Deserves Attention in the Cheap Quarterly Dividend Stocks Category

Core Insights - Gilead Sciences, Inc. is recognized as one of the 11 attractive quarterly dividend stocks to consider for investment [1] - The company is a California-based biopharmaceutical firm that develops innovative treatments for viral hepatitis, COVID-19, and cancer, with a strong pipeline of new drugs anticipated to drive future sales growth [2] - Gilead has a history of enhancing its portfolio through acquisitions, including a recent $350 million deal to acquire Interius BioTherapeutics [2] - The company has been consistently increasing its dividend since its introduction in 2015, currently offering a quarterly dividend of $0.79 per share, resulting in a dividend yield of 2.76% as of September 23 [3] Company Overview - Gilead Sciences specializes in biopharmaceuticals, focusing on treatments for serious diseases [2] - The company's established HIV franchise remains a cornerstone of its business model [3] Financial Performance - Gilead's quarterly dividend of $0.79 per share reflects its commitment to returning value to shareholders [3] - The dividend yield of 2.76% positions Gilead favorably within the biotech industry [3]